Note B - Going Concern and Liquidity	12 Months Ended
Dec. 31, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE B- GOING CONCERN AND LIQUIDITY The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception. At December 31, 2019, the Company’s cash on hand of $1.5 million. Based on the expected cash needed for operating activities, the Company’s current cash and liquidity is not sufficient to finance the operating requirements for at least the next 12 months from the filing date of this annual report. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, the reduction in operating expenses and other strategic plans or transactions. As a result of the reduced hours and closings of dental offices throughout the country and the rest of the world due to the continuing spread of Covid- 19, we anticipate that our revenue for the second quarter, and possibly the third quarter, will be materially and adversely affected. At this point in time, it is too early to determine an estimate of what the second or third quarter impact will be or the effect Covid- 19 may have on our fourth quarter revenue. In addition, it is too early to determine what the effect will be on the anticipated commercialization of our CompuFlow Epidural system as a medical device in 2020. See Note R- Subsequent Events. Management is actively pursuing financing and/or other strategic plans but can provide no assurances that such financing or other strategic plans will be available on acceptable terms, or at all. Further, as a result of the extreme volatility in the financial markets due to the continuing spread of Covid- 19, we may not be able to raise capital when needed or in sufficient amounts or execute other strategic plans or transactions. These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recover ability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern.

NOTE B- GOING CONCERN AND LIQUIDITY

The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within

one

year after the date that the consolidated financial statements are issued. Milestone Scientific has incurred operating losses and negative cash flows from operating activities in virtually each year since its inception. At

December 31, 2019,

the Company’s cash on hand of

$1.5

million. Based on the expected cash needed for operating activities, the Company’s current cash and liquidity is

not

sufficient to finance the operating requirements for at least the next

months from the filing date of this annual report. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.

Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, the reduction in operating expenses and other strategic plans or transactions. As a result of the reduced hours and closings of dental offices throughout the country and the rest of the world due to the continuing spread of Covid-

19,

we anticipate that our revenue for the

second

quarter, and possibly the

third

quarter, will be materially and adversely affected. At this point in time, it is too early to determine an estimate of what the

second

third

quarter impact will be or the effect Covid-

may

have on our

fourth

quarter revenue. In addition, it is too early to determine what the effect will be on the anticipated commercialization of our CompuFlow Epidural system as a medical device in

2020.

See Note R-

Subsequent Events.

Management is actively pursuing financing and/or other strategic plans but can provide

assurances that such financing or other strategic plans will be available on acceptable terms, or at all. Further, as a result of the extreme volatility in the financial markets due to the continuing spread of Covid-

19,

may

not

be able to raise capital when needed or in sufficient amounts or execute other strategic plans or transactions.

These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do

not

include any adjustments to reflect the possible future effects on the recover ability and classification of assets or the amounts and classification of liabilities that

may

result from the inability of the Company to continue as a going concern.